Meghan Bowtell1, Scott Eaton1, Kristen Thien1, Melissa Bardell-Williams1, Linglee Downey1, Aswin Ratheesh2, Eoin Killackey1, Patrick McGorry1, Brian O'Donoghue3. 1. Orygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road Parkville, Victoria 3052, Australia; Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia. 2. Orygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road Parkville, Victoria 3052, Australia; Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia; Orygen Youth Health, 35 Poplar Road, Parkville, Victoria 3052, Australia. 3. Orygen, The National Centre of Excellence in Youth Mental Health, 35 Poplar Road Parkville, Victoria 3052, Australia; Centre for Youth Mental Health, The University of Melbourne, 35 Poplar Road, Parkville, Victoria 3052, Australia; Orygen Youth Health, 35 Poplar Road, Parkville, Victoria 3052, Australia. Electronic address: brian.odonoghue@orygen.org.au.
Abstract
BACKGROUND: There is uncertainty about the required duration of long-term antipsychotic maintenance medication after a first episode of psychosis. Robust predictors of relapse after discontinuation are yet to be identified. The present study aimed to determine the proportion of young people who discontinue their antipsychotic medication after a first episode of psychosis, the proportion who experience relapse, and predictors of relapse. METHODS: A retrospective study of all individuals presenting to the Early Psychosis Prevention and Intervention Centre between 01/01/11 and 31/12/13 was conducted. A Cox regression analysis was conducted to identify predictors of relapse. RESULTS: A total of 544 young people with a FEP were included. A trial of discontinuation was undertaken by 61% of the cohort. Median duration of antipsychotic medication prior to first trial of discontinuation was 174.50days. Amongst those trialing discontinuation, 149 (45.8%) experienced relapse in a median follow-up time post discontinuation of 372days. On multivariate analysis, predictors of relapse were a diagnosis of cannabis abuse disorder (HR: 1.40), and longer duration of antipsychotic medication (HR: 1.05). CONCLUSION: Antipsychotic discontinuation frequently occurs earlier than guidelines recommend. Individuals with a diagnosis of cannabis abuse are more likely to experience relapse and addressing this substance abuse prior to discontinuation could possibly reduce relapse rates.
BACKGROUND: There is uncertainty about the required duration of long-term antipsychotic maintenance medication after a first episode of psychosis. Robust predictors of relapse after discontinuation are yet to be identified. The present study aimed to determine the proportion of young people who discontinue their antipsychotic medication after a first episode of psychosis, the proportion who experience relapse, and predictors of relapse. METHODS: A retrospective study of all individuals presenting to the Early Psychosis Prevention and Intervention Centre between 01/01/11 and 31/12/13 was conducted. A Cox regression analysis was conducted to identify predictors of relapse. RESULTS: A total of 544 young people with a FEP were included. A trial of discontinuation was undertaken by 61% of the cohort. Median duration of antipsychotic medication prior to first trial of discontinuation was 174.50days. Amongst those trialing discontinuation, 149 (45.8%) experienced relapse in a median follow-up time post discontinuation of 372days. On multivariate analysis, predictors of relapse were a diagnosis of cannabis abuse disorder (HR: 1.40), and longer duration of antipsychotic medication (HR: 1.05). CONCLUSION: Antipsychotic discontinuation frequently occurs earlier than guidelines recommend. Individuals with a diagnosis of cannabis abuse are more likely to experience relapse and addressing this substance abuse prior to discontinuation could possibly reduce relapse rates.
Authors: Kari M Ersland; Lene S Myrmel; Even Fjære; Rolf K Berge; Lise Madsen; Vidar M Steen; Silje Skrede Journal: Int J Neuropsychopharmacol Date: 2019-05-01 Impact factor: 5.176
Authors: P Takács; P Czobor; L Fehér; J Gimesi-Országh; P Fadgyas-Freyler; M Bacskai; P Rakonczai; A Borsi; R Hegyi; T Németh; J Sermon; I Bitter Journal: PLoS One Date: 2019-06-13 Impact factor: 3.240
Authors: Seoyoung Kim; Sang Ho Shin; Barbara Santangelo; Mattia Veronese; Seung Kwan Kang; Jae Sung Lee; Gi Jeong Cheon; Woojoo Lee; Jun Soo Kwon; Oliver D Howes; Euitae Kim Journal: Mol Psychiatry Date: 2020-09-14 Impact factor: 15.992
Authors: Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij Journal: Front Psychiatry Date: 2018-11-13 Impact factor: 4.157